Posted Nov. 28, 2011 at 12:15 p.m.
Treximet
Image 1 of 2 · Next Image…
Research Triangle Park, N.C. — The money strengthens Pozen's negotiating position as it seeks a partner for a drug under development and does so without diluting Pozen's shareholders, CEO John PlatchetkaCopyright 2013 MedCity. All rights reserved.
Pozen's $75M deal - It's all about cash for product pipeline
Post a comment
Print this blog postE-mail blog post
Share
Treximet
Image 1 of 2 · Next Image…
Research Triangle Park, N.C. — The money strengthens Pozen's negotiating position as it seeks a partner for a drug under development and does so without diluting Pozen's shareholders, CEO John PlatchetkaCopyright 2013 MedCity. All rights reserved.
Log in or upgrade to view WRALTechWire Insider content
To access this premium content and other benefits, become a WRAL TechWire Insider. Daily, monthly, and annual memberships available.
Please Log In to add a comment.
Best of TechWire Insider
OUR INSIDERS
WRAL TechWire Editor
The Skinny
Raleigh-based PRA International eyes public offering- Will lightning strike again for veteran entrepreneur Brian Handly at StepLeader?
- Raleigh app developer StepLeader lands $4.4M in first fund raiser
- IBM opens Linux center in China, says it will work with Red Hat
- Red-hot Raleigh startup WedPics hauls in $1.1M in funding
- New Triangle venture capital firm slowly emerging from shadows
- Titans of tech seek to excite UNC, Duke grads about a future beyond themselves
- Triangle politician tries to accelerate crowdfunding; bill passes first hurdle
- ChannelAdvisor seeks $80M, sets share target price for IPO
- IT job openings 28% below 2012 numbers, report shows